Sign inJoin waitlistJoin the waitlist

Sarah Crafton

Director, Gynecologic Oncology Clinical Trial Program · Allegheny Health Network Medical Education Consortium

Credentials: · · · · ·

History

DREXEL UNIVERSITY
Present

Gynecologic Oncology
Allegheny Health Network Medical Education Consortium
2017–2020
Obstetrics and Gynecology
Ohio State University Hospital
2013–2017
Northeast Ohio Medical University
2007–2011

Research

Cancer and pregnancy: an overview for obstetricians and gynecologists
Review · American Journal of Obstetrics and Gynecology · 2014 · Last of 3 authors · 90 citations
Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer
Review · Clinical Therapeutics · 2016 · First of 2 authors · 65 citations
Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries
Cancer · 2020 · First of 6 authors · 33 citations

Ritu Salani
6 papers
Thomas Krivak
6 papers
David Cohn
5 papers
Eirwen Miller
5 papers
Floor Backes
5 papers · 2 as a fellow
Caroline Billingsley
3 papers · 3 as a fellow
David O'Malley
3 papers
Kathleen Moore
3 papers
Larry Copeland
3 papers
Premal Thaker
3 papers
Zachary Horne
3 papers · 2 as a resident
Adrian Suarez
2 papers

Clinical trials

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 2
MacroGenics
2025–2027
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Site PI · Recruiting · Phase 3
Genelux Corporation
2022–2027
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027